

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

CD3

RRID:AB_396890

Type: Antibody

Proper Citation

BD Biosciences Cat# 557832, RRID:AB_396890

Antibody Information

URL: http://antibodyregistry.org/AB_396890

Proper Citation: BD Biosciences Cat# 557832, RRID:AB_396890

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD3

Description: This monoclonal targets CD3

Target Organism: human

Antibody ID: AB_396890

Vendor: BD Biosciences

Catalog Number: 557832

Record Creation Time: 20250820T045625+0000

Record Last Update: 20250820T202047+0000

Ratings and Alerts

No rating or validation information has been found for CD3.

No alerts have been found for CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Kaginkar S, et al. (2026) Immune and viral surveillance of HIV-1C reservoirs in an Indian cohort. *iScience*, 29(1), 114278.

van Meijgaarden KE, et al. (2025) Sera contributing to mycobacterial growth restriction in vitro display enhanced Fc-mediated phagocytosis. *iScience*, 28(5), 112504.

Fan Y, et al. (2025) Exosomal Galectin-3 promotes peritoneal metastases in gastric adenocarcinoma via microenvironment alterations. *iScience*, 28(1), 111564.

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. *Cell reports. Medicine*, 102360.

De Sanctis F, et al. (2024) Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. *Immunity*, 57(6), 1378.

von Loeffelholz C, et al. (2024) Increased peritoneal B1-like cells during acute phase of human septic peritonitis. *iScience*, 27(7), 110133.

Deng S, et al. (2024) C5a enhances inflammation and chemotaxis of ?? T cells in malignant pleural effusion. *International immunopharmacology*, 127, 111332.

Pandit S, et al. (2024) Implantable CAR T cell factories enhance solid tumor treatment. *Biomaterials*, 308, 122580.

Albanese M, et al. (2024) Receptor transfer between immune cells by autoantibody-enhanced, CD32-driven trogocytosis is hijacked by HIV-1 to infect resting CD4 T cells. *Cell reports. Medicine*, 5(4), 101483.

Ma H, et al. (2024) Disparate macrophage responses are linked to infection outcome of Hantan virus in humans or rodents. *Nature communications*, 15(1), 438.

Wang X, et al. (2024) *Fusobacterium nucleatum* facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. *Cancer cell*, 42(10), 1729.

Furukawa Y, et al. (2023) iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer. *Cell reports. Medicine*, 4(12), 101327.

Long KD, et al. (2023) Chimerism and phenotypic analysis of intraepithelial and lamina propria T cells isolated from human ileal biopsies after intestinal transplantation. *STAR*

protocols, 4(2), 102192.

Deng S, et al. (2023) C5a enhances V β 1 T cells recruitment via the CCL2-CCR2 axis in IgA nephropathy. *International immunopharmacology*, 125(Pt A), 111065.

Umeda M, et al. (2022) Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. *Blood cancer discovery*, 3(3), 194.

Sangesland M, et al. (2022) Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus. *Immunity*, 55(9), 1693.

Shangguan S, et al. (2021) Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. *eLife*, 10.

de Jonge K, et al. (2021) Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients. *Oncoimmunology*, 10(1), 1873585.

Nganou-Makamdop K, et al. (2021) Translocated microbiome composition determines immunological outcome in treated HIV infection. *Cell*, 184(15), 3899.

Kim DH, et al. (2021) Induction of the IL-1RII decoy receptor by NFAT/FOXP3 blocks IL-1 β -dependent response of Th17 cells. *eLife*, 10.